DelveInsight’s ‘Lennox Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Lennox Gastaut Syndrome (LGS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Lennox Gastaut Syndrome (LGS) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted LGS symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lennox Gastaut Syndrome (LGS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017–2030
Lennox Gastaut Syndrome (LGS) Overview
Lennox–Gastaut syndrome (LGS) is a rare and severe form of epilepsy that begins in childhood. It belongs to the group of the severe infantile epileptic syndrome (neonatal epileptic encephalopathy with suppression-burst, West syndrome, severe myoclonic epilepsy of infancy).Affected children experience several different types of seizures, most commonly atonic, tonic and atypical absence seizures but generalized tonic-clonic and partial seizures can occur as well.
Three main criteria that define LGS are Multiple seizure types, mainly generalized, Abnormal electroencephalogram (EEG) with generalized slow spike-and-wave discharges (SSW) at <2.5 Hz, Mental retardation or learning disabilities.
People with Lennox–Gastaut syndrome begin having frequent seizures in early childhood, usually between ages 3 and 5. LGS is also a physically dangerous epilepsy syndrome of childhood because of the frequent falls, injuries, and cognitive impairment that can severely limit the quality of life. Children affected might previously have infantile spasms or underlying brain disorder, but etiology can be idiopathic also.
In general, the causes of LGS is divided into two broader groups ; Identifiable causes, Cryptogenic (non-identifiable) causes. Identifiable causes include brain damage (e.g., head trauma), perinatal complications (e.g., birth asphyxia, intrauterine growth retardation, kernicterus), congenital central nervous system malformations (e.g., tuberous sclerosis), infections (e.g., meningitis, sepsis), or metabolic disorders.
Several key investigations are recommended for the difficulties mentioned above that are associated with diagnosed LGS.
Lennox Gastaut Syndrome (LGS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Lennox Gastaut Syndrome (LGS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Lennox Gastaut Syndrome (LGS) market report gives a thorough understanding of LGS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides LGS symptoms of treatment algorithms and treatment guidelines for LGS symptoms in the US, Europe, and Japan.
Lennox Gastaut Syndrome symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Lennox Gastaut Syndrome (LGS) epidemiology segmented as the Total Prevalent cases of Lennox Gastaut Syndrome (LGS), Diagnosed Prevalent Cases of Lennox Gastaut Syndrome (LGS), Gender-Specific cases of Lennox Gastaut Syndrome (LGS), Seizure-specific cases of Lennox Gastaut Syndrome (LGS). The report includes the prevalent scenario of LGS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Lennox Gastaut Syndrome (LGS) Epidemiology
The epidemiology segment also provides the Lennox Gastaut Syndrome (LGS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent population of Lennox Gastaut Syndrome (LGS) in 7MM countries was estimated to be 111,798 cases in 2017.
The drug chapter segment of the Lennox Gastaut Syndrome (LGS) report encloses the detailed analysis of LGS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lennox Gastaut Syndrome (LGS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Valproate (Valproic acid) is one of the most useful initial medication of choice to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, juvenile myoclonic epilepsy, and the seizures associated with Lennox-Gastaut syndrome.
Products detail in the report…
Lennox Gastaut Syndrome (LGS) Emerging Drugs
Fycompa (Perampanel): Eisai
Fycompa (Perampanel) is a non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4¬ isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons.
As it has been approved for multiple seizures, this may give an advantage in Lennox–Gastaut Syndrome (LGS) too. It is being developed for LGS in the phase III stage of clinical studies by Eisai Pharmaceuticals. The drug is a schedule III controlled substance and has the potential to be abused and leads to drug dependence. The US Drug Enforcement Administration has designated Fycompa as a federally-controlled substance (CIII).
Products detail in the report…
The Lennox Gastaut Syndrome (LGS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Lennox Gastaut Syndrome (LGS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Lennox Gastaut Syndrome (LGS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Lennox Gastaut Syndrome (LGS) market in 7MM is expected to change in the study period 2017–2030.
Key Findings
This section includes a glimpse of the Lennox Gastaut Syndrome (LGS) market in 7MM. The market size of LGS in the seven major markets was found to be USD 136.6 million in 2017.
The United States Market Outlook
This section provides a total of Lennox Gastaut Syndrome (LGS) market size and market size by therapies in the United States.
The United States accounts for the highest market size of LGS in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Valproate is considered as the first line of therapy for LGS as it is effective against a wide spectrum of seizures, the drug is administered as a monotherapy and if ineffective another drug such as lamotrigine, topiramate, rufinamide or clobazam may be added. It also has significant side effects ranging from tremor to reduction in platelet count and function as well as hyperammonemia.
Surgical therapy is usually recommended to those patients who do not respond to the usual seizure medications or other therapies available. Most commonly used surgical therapies are corpus callosotomy and Vagus Nerve Stimulator (VNS) along with other less commonly used therapies RNS stimulator, deep brain stimulator and trigeminal nerve stimulation. Corpus callosotomy is most effective for atonic seizures ("drop attacks"), tonic-clonic seizures, and tonic seizures whereas VNS control seizures through electrical impulses.
A number of drugs have been approved by the US Food and Drug Administration (FDA) for the treatment of Lennox-Gastaut syndrome including Epidiolex, Topamax, Banzel, Lamictal, Felbatol, Onfi and Klonopin. Interestingly, none of these are the typical first choice of treatment
EU-5 Countries: Market Outlook
The total Lennox Gastaut Syndrome (LGS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Numerous treatment approaches are currently used in Europe to treat LGS, including use of conventional antiepileptic drugs (most commonly sodium valproate, lamotrigine and topiramate), other drug interventions (corticosteroids and intravenous immunoglobulin) and nonpharmacologic treatments (ketogenic diet, corpus callosotomy and vagus nerve stimulation).
Rufinamide is one of the approved drug in EU5. It is structurally unrelated to any other antiseizure compound and has good efficacy against various seizure types associated with LGS.
Japan Market Outlook
The total of Lennox Gastaut Syndrome (LGS) market size and market size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Lennox Gastaut Syndrome (LGS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Lennox Gastaut Syndrome (LGS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Lennox Gastaut Syndrome (LGS) key players involved in developing targeted therapeutics.
Major players include Perampanel (Eisai Pharmaceuticals), ZX-008 (Zogenix International Limited) and TAK-935 (Takeda/ Ovid).
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Lennox Gastaut Syndrome (LGS) emerging therapies.
Cannabidiol oral solution was approved by the EMA in September 2019 while by FDA it was approved in 2018, and received marketing authorization under the trade name Epidiolex as adjunctive therapy for seizures associated with LGS or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. Following this approval, GW has been working with the relevant bodies in the UK, Germany, Spain, France, and Italy to secure reimbursement ahead of the anticipated launch of the medicine in these countries.
To keep up with current market trends, we take KOLs and SME’s opinion working in Lennox Gastaut Syndrome (LGS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or the Lennox Gastaut Syndrome (LGS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive & Market Intelligence analysis of the Lennox Gastaut Syndrome (LGS) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Lennox Gastaut Syndrome (LGS): Market Overview at a Glance
2.1. Market Share (%) Distribution of LGS in 2017
2.2. Market Share (%) Distribution of LGS in 2030
3. Executive summary
4. Organizations
5. Disease Overview: Lennox Gastaut Syndrome (LGS)
5.1. Introduction
5.2. Classification
5.3. Signs and Symptoms
5.4. Types of Seizures associated with LGS
5.5. Etiology
5.6. Pathogenesis
5.7. Diagnosis
5.7.1. Differential Diagnosis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)
6.3. 7MM Total Diagnosed Prevalent Patient Population of Lennox Gastaut Syndrome (LGS)
6.4. Country Wise-Epidemiology of Lennox Gastaut Syndrome (LGS)
6.5. United States
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Cases of Lennox Gastaut Syndrome in the United States
6.5.3. Diagnosed Prevalent Cases of Lennox Gastaut Syndrome in the United States
6.5.4. Gender-specific Diagnosed Prevalent Cases of LGS in the United States
6.5.5. Seizure-specific Diagnosed Prevalent Cases of LGS in the United States
6.6. Germany
6.6.1. Assumptions and Rationale
6.6.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Germany
6.6.3. Diagnosed Prevalent Cases of LGS in Germany
6.6.4. Gender-specific Diagnosed Prevalent Cases of LGS in Germany
6.6.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Germany
6.7. France
6.7.1. Assumptions and Rationale
6.7.2. Total Prevalent Cases of Lennox Gastaut Syndrome in France
6.7.3. Diagnosed Prevalent Cases of LGS in France
6.7.4. Gender-specific Diagnosed Prevalent Cases of LGS in France
6.7.5. Seizure-specific Diagnosed Prevalent Cases of LGS in France
6.8. Italy
6.8.1. Assumptions and Rationale
6.8.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Italy
6.8.3. Diagnosed Prevalent Cases of LGS in Italy
6.8.4. Gender-specific Diagnosed Prevalent Cases of LGS in Italy
6.8.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Italy
6.9. Spain
6.9.1. Assumptions and Rationale
6.9.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Spain
6.9.3. Diagnosed Prevalent Cases of LGS in Spain
6.9.4. Gender-specific Diagnosed Prevalent Cases of LGS in Spain
6.9.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Spain
6.10. United Kingdom
6.10.1. Assumptions and Rationale
6.10.2. Total Prevalent Cases of Lennox Gastaut Syndrome in the United Kingdom
6.10.3. Diagnosed Prevalent Cases of LGS in the United Kingdom
6.10.4. Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom
6.10.5. Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom
6.11. Japan
6.11.1. Assumptions and Rationale
6.11.2. Total Prevalent Cases of Lennox Gastaut Syndrome in Japan
6.11.3. Diagnosed Prevalent Cases of LGS in Japan
6.11.4. Gender-specific Diagnosed Prevalent Cases of LGS in Japan
6.11.5. Seizure-specific Diagnosed Prevalent Cases of LGS in Japan
7. Current Treatment Practices
7.1. Treatment Algorithm
7.2. Treatment Guidelines
7.2.1. NICE Guidelines
7.2.2. American Academy of Neurology (AAN)
8. Unmet needs
9. Marketed drugs
9.1. Lamictal: GlaxoSmithKline
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Safety and Efficacy
9.1.5. Product Profile
9.2. Felbatol: Meda Pharmaceuticals
9.2.1. Drug Description
9.2.2. Mechanism of Action
9.2.3. Product Developmental Activities
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Klonopin: Roche
9.3.1. Drug Description
9.3.2. Mechanism of Action
9.3.3. Regulatory Milestones
9.4. Onfi: Lundbeck
9.4.1. Drug Description
9.4.2. Mechanism of Action
9.4.3. Regulatory Milestones
9.4.4. Product Developmental Activities
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. Epidiolex: Greenwich Biosciences
9.5.1. Drug Description
9.5.2. Mechanism of Action
9.5.3. Regulatory Milestones
9.5.4. Clinical Trials
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Banzel: Janssen Pharmaceuticals
9.6.1. Drug Description
9.6.2. Mechanism of action
9.6.3. Regulatory Milestones
9.6.4. Advantages & Disadvantages
9.6.5. Clinical Trials
9.6.6. Safety and Efficacy
9.6.7. Product Profile
9.7. Topamax: Janssen Pharmaceuticals
9.7.1. Product Description
9.7.2. Mechanism of Action
9.7.3. Regulatory Milestones
9.7.4. Clinical Trials
9.7.5. Safety and Efficacy
9.7.6. Product Profile
10. Emerging Therapies
10.1. Key cross competition
10.2. Phase-III Drugs
10.3. Fycompa (Perampanel): Eisai
10.3.1. Product Description
10.3.2. Clinical Development
10.3.3. Safety and Efficacy
10.3.4. Product Profile
10.4. Fintepla (ZX 008): Zogenix
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Safety and Efficacy
10.4.5. Product Profile
10.5. Phase-II Drugs
10.6. TAK-935/ OV935: Takeda/Ovid
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
11. Lennox Gastaut Syndrome: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Lennox Gastaut Syndrome (LGS) in 7MM
12. Market Outlook by Country
13. The United States: Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of LGS in the United States
13.1.2. Therapy Based Market Size of LGS in the US
13.2. EU-5 Countries: Market Outlook
13.3. Germany
13.3.1. Total Market size of LGS in Germany
13.3.2. Therapy Based Market Size of LGS in Germany
13.4. France
13.4.1. Total Market size of LGS in France
13.4.2. Therapy Based Market Size of LGS in France
13.5. Italy
13.5.1. Total Market size of LGS in Italy
13.5.2. Therapy Based Market Size of LGS in Italy
13.6. Spain
13.6.1. Total Market size of LGS in Spain
13.6.2. Therapy Based Market Size of LGS in Spain
13.7. United Kingdom
13.7.1. Total Market size of LGS in the United Kingdom
13.7.2. Therapy Based Market Size of LGS in the UK
13.8. Japan: Market Outlook
13.8.1. Total Market size of LGS in Japan
13.8.2. Therapy Based Market Size of LGS in Japan
14. Market Drivers
15. Market Barriers
16. Market access and Reimbursement
17. SWOT Analysis
18. Case studies
18.1. Epilepsy in Christianson syndrome: Case of Lennox–Gastaut syndrome
18.2. A Case of Lennox–Gastaut Syndrome in a 6-Year-Old Child with Moyamoya Disease
19. KOL Views
20. Appendix
21. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
List of Table
Table 1: Features of various epileptic syndromes
Table 2: Genetic tests that might elucidate LGS genetic etiology and diagnosis
Table 3: Total Prevalent Patient Population of LGS in 7MM (2017-2030)
Table 4: Total Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2030)
Table 5: Total Prevalent Cases of LGS in the United States (2017-2030)
Table 6: Total Diagnosed Prevalent Cases of LGS in the United States (2017-2030)
Table 7: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)
Table 8: Seizure-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)
Table 9: Total Prevalent Cases of LGS in Germany (2017-2030)
Table 10: Total Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Table 11: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Table 12: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Table 13: Total Prevalent Cases of LGS in France (2017-2030)
Table 14: Total Diagnosed Prevalent Cases of LGS in France (2017-2030)
Table 15: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)
Table 16: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)
Table 17: Total Prevalent Cases of LGS in Italy (2017-2030)
Table 18: Total Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Table 19: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Table 20: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Table 21: Total Prevalent Cases of LGS in Spain (2017-2030)
Table 22: Total Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Table 23: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Table 24: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Table 25: Total Prevalent Cases of LGS in the UK (2017-2030)
Table 26: Total Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)
Table 27: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)
Table 28: Seizure-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)
Table 29: Total Prevalent Cases of LGS in Japan (2017-2030)
Table 30: Total Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Table 31: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Table 32: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Table 33: Anti-seizure drugs and their applications
Table 34: A summary reference guide to pharmacological treatment
Table 35: Licensing indications of the guideline AEDs
Table 36: AAN-Recommendations
Table 37: Emerging Drugs Analysis, 2020
Table 38: Perampanel, Clinical Trial Description, 2020
Table 39: ZX008, Clinical Trial Description, 2020
Table 40: TAK-935, Clinical Trial Description, 2020
Table 41: 7 Major Market Size of LGS in USD Million (2017-2030)
Table 42: United States Market Size of LGS in USD Million (2017-2030)
Table 43: Therapy Based Market Size of LGS in the US in USD Million (2017-2030)
Table 44: Germany Market Size of LGS in USD Million (2017-2030)
Table 45: Therapy Based Market Size of LGS in Germany in USD Million (2017-2030)
Table 46: France Market Size of LGS in USD Million (2017-2030)
Table 47: Therapy Based Market Size of LGS in France in USD Million (2017-2030)
Table 48: Italy Market Size of LGS in USD Million (2017-2030)
Table 49: Therapy Based Market Size of LGS in Italy in USD Million (2017-2030)
Table 50: Spain Market Size of LGS in USD Million (2017-2030)
Table 51: Therapy Based Market Size of LGS in Spain in USD Million (2017-2030)
Table 52: UK Market Size of LGS in USD Million (2017-2030)
Table 53: Therapy Based Market Size of LGS in the UK in USD Million (2017-2030)
Table 54: Japan Market Size of LGS in USD Million (2017-2030)
Table 55:Therapy Based Market Size of LGS in Japan in USD Million (2017-2030)
List of Figure
Figure 1: ILAE Classification of Seizure type Basic Version
Figure 2: ILAE Classification of Seizure type Expanded Version
Figure 3: Etiology of LGS
Figure 4: Symptomatic Causes of LGS
Figure 5: Proposed scheme for the pathogenesis of Lennox–Gastaut syndrome based on clinical and experimental data relevant to LGS
Figure 6: Classical diagnostic criteria for LGS
Figure 7: Total Prevalent Patient Population of LGS in 7MM (2017-2030)
Figure 8: Total Diagnosed Prevalent Patient Population of LGS in 7MM (2017-2030)
Figure 9: Total Prevalent Cases of LGS in the United States (2017-2030)
Figure 10: Diagnosed Prevalent Cases of LGS in the United States (2017-2030)
Figure 11: Gender-specific Diagnosed Prevalent Cases of LGS in the United States (2017-2030)
Figure 12: Seizure-specific Diagnosed Prevalent Cases of LGS in the US (2017-2030)
Figure 13: Total Prevalent Cases of LGS in Germany (2017-2030)
Figure 14: Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Figure 15: Gender-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Figure 16: Seizure-specific Diagnosed Prevalent Cases of LGS in Germany (2017-2030)
Figure 17: Total Prevalent Cases of LGS in France (2017-2030)
Figure 18: Diagnosed Prevalent Cases of LGS in France (2017-2030)
Figure 19: Gender-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)
Figure 20: Seizure-specific Diagnosed Prevalent Cases of LGS in France (2017-2030)
Figure 21: Total Prevalent Cases of LGS in Italy (2017-2030)
Figure 22: Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Figure 23: Gender-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Figure 24: Seizure-specific Diagnosed Prevalent Cases of LGS in Italy (2017-2030)
Figure 25: Total Prevalent Cases of LGS in Spain (2017-2030)
Figure 26: Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Figure 27: Gender-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Figure 28: Seizure-specific Diagnosed Prevalent Cases of LGS in Spain (2017-2030)
Figure 29: Total Prevalent Cases of LGS in the UK (2017-2030)
Figure 30: Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)
Figure 31: Gender-specific Diagnosed Prevalent Cases of LGS in the United Kingdom (2017-2030)
Figure 32: Seizure-specific Diagnosed Prevalent Cases of LGS in the UK (2017-2030)
Figure 33: Total Prevalent Cases of LGS in Japan (2017-2030)
Figure 34: Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Figure 35: Gender-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Figure 36: Seizure-specific Diagnosed Prevalent Cases of LGS in Japan (2017-2030)
Figure 37: Treatment Algorithm of LGS
Figure 38: Unmet needs of LGS
Figure 39: 7 Major Market Size of LGS in USD Million (2017-2030)
Figure 40: Market Size of LGS in the United States, USD Millions (2017-2030)
Figure 41: Therapy Based Market Size of LGS in the US in USD Million (2017-2030)
Figure 42: Market Size of LGS in Germany, USD Millions (2017-2030)
Figure 43: Therapy Based Market Size of LGS in Germany in USD Million (2017-2030)
Figure 44: Market Size of LGS in France USD Millions (2017-2030)
Figure 45: Therapy Based Market Size of LGS in France in USD Million (2017-2030)
Figure 46: Market Size of LGS in Italy, USD Millions (2017-2030)
Figure 47: Therapy Based Market Size of LGS in Italy in USD Million (2017-2030)
Figure 48: Market Size of LGS in Spain, USD Millions (2017-2030)
Figure 49: Therapy Based Market Size of LGS in Spain in USD Million (2017-2030)
Figure 50: Market Size of LGS in the United Kingdom, USD Millions (2017-2030)
Figure 51: Therapy Based Market Size of LGS in the UK in USD Million (2017-2030)
Figure 52: Market Size of LGS in Japan, USD Millions (2017-2030)
Figure 53: Therapy Based Market Size of LGS in Japan in USD Million (2017-2030)
Figure 54: Market Drivers
Figure 55:Market Barriers
GlaxoSmithKline
Meda Pharmaceuticals
Roche
Lundbeck
Greenwich Biosciences
Janssen Pharmaceuticals
Eisai
Zogenix
Takeda/Ovid
